CARGO Therapeutics, Inc. (NASDAQ:CRGX – Get Free Report) CFO Anup Radhakrishnan sold 1,600 shares of the stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $25.28, for a total value of $40,448.00. Following the transaction, the chief financial officer now directly owns 6,446 shares in the company, valued at approximately $162,954.88. The transaction was disclosed in a filing with the SEC, which is available at this link.
CARGO Therapeutics Trading Down 4.6 %
Shares of CRGX stock opened at $23.85 on Friday. CARGO Therapeutics, Inc. has a 12 month low of $13.14 and a 12 month high of $33.92. The firm has a fifty day moving average price of $18.09 and a 200 day moving average price of $19.53.
CARGO Therapeutics (NASDAQ:CRGX – Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($1.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.04. On average, sell-side analysts expect that CARGO Therapeutics, Inc. will post -4.37 earnings per share for the current year.
Wall Street Analyst Weigh In
Check Out Our Latest Report on CRGX
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. purchased a new stake in CARGO Therapeutics during the 1st quarter valued at approximately $48,000. American International Group Inc. purchased a new stake in shares of CARGO Therapeutics during the first quarter worth approximately $237,000. BNP Paribas Financial Markets acquired a new stake in shares of CARGO Therapeutics during the first quarter worth $238,000. California State Teachers Retirement System purchased a new position in CARGO Therapeutics in the 1st quarter valued at $337,000. Finally, Rhumbline Advisers increased its stake in CARGO Therapeutics by 14.0% in the 2nd quarter. Rhumbline Advisers now owns 30,639 shares of the company’s stock valued at $503,000 after buying an additional 3,765 shares during the period. 93.16% of the stock is currently owned by institutional investors and hedge funds.
About CARGO Therapeutics
CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.
See Also
- Five stocks we like better than CARGO Therapeutics
- What is a Special Dividend?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What Are Dividend Challengers?
- MarketBeat Week in Review – 9/16 – 9/20
- How to Buy Cheap Stocks Step by Step
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for CARGO Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CARGO Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.